Clearmind Medicine (NASDAQ: CMND) Expands Enrollment in CMND-100 AUD Trial

March 11, 2026

Expert Analysis Clearmind Medicine Inc. (NASDAQ: CMND) continues to demonstrate its commitment to advancing therapies for Alcohol Use Disorder (AUD) by actively enrolling participants in the third cohort of its Phase I/IIa clinical trial. The company’s focus on developing non-hallucinogenic neuroplastogen-derived drugs like CMND-100 represents a strategic approach aimed at addressing an unmet medical need with potentially improved patient compliance and safety profiles. The expansion of recruitment at leading institutions…

Read More >>